Met Life Investment Management, LLC Aadi Bioscience, Inc. Transaction History

Met Life Investment Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Apr 29, 2024	BUY	$6.84 - $8.56 $59,460 - $74,412	8,693 New	8,693 $59,000
Q2 2023 Aug 10, 2023	BUY	$6.84 - $8.56 $59,460 - $74,412	8,693 New	8,693 $59,000
Q4 2022 May 10, 2024	SELL	$11.99 - $14.5 $1,570 - $1,899	-131 Reduced 1.68%	7,671 $98,000
Q4 2022 Jun 14, 2023	BUY	$11.99 - $14.5 $91,975 - $111,229	7,671 New	7,671 $98,000
Q4 2022 Mar 22, 2023	SELL	$11.99 - $14.5 $1,570 - $1,899	-131 Reduced 1.68%	7,671 $98,000
Q4 2022 Feb 15, 2023	BUY	$11.99 - $14.5 $91,975 - $111,229	7,671 New	7,671 $98,000
Q2 2022 May 10, 2024	BUY	$11.57 - $17.92 $90,269 - $139,811	7,802 New	7,802 $96,000
Q2 2022 Jun 20, 2023	BUY	$11.57 - $17.92 $90,269 - $139,811	7,802 New	7,802 $96,000
Q2 2022 Mar 22, 2023	BUY	$11.57 - $17.92 $1,515 - $2,347	131 Added 1.71%	7,802 $96,000
Q2 2022 Aug 11, 2022	BUY	$11.57 - $17.92 $90,269 - $139,811	7,802 New	7,802 $96,000

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $78.4M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.